CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner

Abstract

ObjectivesDiabetic retinopathy (DR) is a severe complication of chronic diabetes. The C1q/TNF-related protein family (CTRPs) has been demonstrated to exert protective effects against obesity and atherosclerosis in animal studies. Heretofore, the association between circulating CTRPs and DR patients has been unexplored. In the current study, we attempt to define this association, as well as the effect of CTRPs upon DR pathophysiology.DesignThe present investigation is a case control study that enrolled control subjects and type 2 diabetes mellitus (T2DM) patients diagnosed with DR. Serum CTRPs and sVACM-1 were determined by ELISA.ResultsSerum CTRP3 and CTRP5 levels were markedly decreased in patients with T2DM compared to controls (p<0.05) and inversely associated with T2DM. Furthermore, mutivariate regression and ROC analysis revealed CTRP3 deficiency, not CTRP5, was associated with proliferative diabetic retinopathy (PDR). Spearman’s rank correlation assay demonstrated an inverse association between CTRP3 and sVCAM-1. Finally, exogenous CTRP3 administration attenuated high glucose high lipid (HGHL)-induced VCAM-1 production in an AMPK-dependent manner in cultured human retinal microvascular endothelial cells (HRMECs).ConclusionCTRP3 may serve as a novel biomarker for DR severity. CTRP3 may represent a future novel therapeutic against DR, a common ocular complication of diabetes.

Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study

“…The expenditure of each indexes were calculated, based on the website of Beijing Medical Service [13].…”

Adipose tissue-derived cytokines, CTRPs as biomarkers and therapeutic targets in metabolism and the cardiovascular system

“…CTRP6, although it has no effect on collagen or fibroblasts proliferation, does suppress in response to alterations in energy state and predicting changes in the metabolic circuit [21] . Therefore, among the CTRPs, CTRP1 displays the potential to serve as a marker and therapeutic target in the vascular system and CTRP3 exhibits biomarker features in patients with diabetic-related PDR [45] . CTRP5 appears to have a greater potential to serve as a biomarker to predict the risks in PCI following the clinical operations.…”

CTRP3 inhibits high glucose–induced human glomerular mesangial cell dysfunction

“…HG exposure of glomerular MCs can activate the JAK2/STAT3 signaling cascades, thus stimulating excessive proliferation and growth of glomerular MCs. [15][16][17] Recently, one study showed that blood levels of CTRP3 are decreased in diet-induced obese mice, and recombinant CTRP3 infusion could suppress blood glucose in wild-type, obese, and diabetic mice. This family is involved in the pathogenesis of various diseases, including atherosclerosis, liver disease, insulin resistance, and kidney disease.…”